close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

VivoSim Labs, Inc. - Common Stock (NQ:VIVS)

0.1464 +0.0170 (+13.14%)
Delayed Quote Updated: 2:18 PM EST, Nov 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about VivoSim Labs, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
A Billionaire Investor Links Cancer Treatment and Wireless Technology as AI Pharmaceutical Testing Gains Ground
Via AB Newswire
Topics Artificial Intelligence
News headline image
VivoSim Labs to Showcase Multiparametric Human 3D Tissue Safety Data at the American College of Toxicology (ACT) 47th Annual Meeting
Company to feature two scientific poster presentations highlighting that its multiparametric approach delivers superior predictive power for both its DILI risk stratification and gastrointestinal... 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
Post-Midterm Market Sectors and Companies Inside to Watch
Via AB Newswire
News headline image
3 Stocks Under $1: INO, VIVS, FNUC in Focus for November
Via AB Newswire
News headline image
VivoSim Labs and Chemveda Life Sciences Join Forces to Put AI-Designed Drug Candidates to the Human Test
Collaboration closes the loop between AI drug design and human biology: Chemveda designs and makes the molecules, VivoSim’s NAMkind™ 3D human liver and intestine models show which ones are safe to... 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
Next-Gen Biotech: RXRX, OCGN, SNTI, VIVS, ONCO Stocks to Watch
Via AB Newswire
Topics Artificial Intelligence
News headline image
VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling
Patient-derived liver and intestinal disease models are designed to help drug developers test whether a candidate reduces human disease in tissue before it reaches clinical trials 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
5 Biotech Stocks’ TCRT, IGC, PDSB, PFAI, Acquisition, Alzheimer’s, Cardio and Cancer Research Milestones
Via AB Newswire
Topics Artificial Intelligence
News headline image
4 Low-Priced Listed Stocks: VIVS, IGC, RIME, TOPP, With Catalysts to Watch
Via AB Newswire
Topics Animal Testing Artificial Intelligence
News headline image
VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods
As the FDA opens the door to non-animal safety testing, VivoSim's human-relevant models are already helping lower drug costs 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
2026 Biotech Watchlist IBRX, PACB, IGC, VIVS Lead 7 Stocks in Focus
Via AB Newswire
News headline image
2026 Nanocap Stocks to Watch: IGC, KNRX, GYGY, ARAY Lead Watchlist Now See More Inside!
Via AB Newswire
Topics Artificial Intelligence
News headline image
VivoSim Labs Inc. (NASDAQ: VIVS) Targets the Multibillion-Dollar Cost of Failed Drugs
Via AB Newswire
News headline image
Greenland Stocks in Focus: GLND, GRML, CRML Lead the Watchlist More Names Inside
Via AB Newswire
Topics Government
News headline image
VivoSim Labs Inc. (NASDAQ: VIVS) Takes Aim at Pharma’s 92% Drug-Failure Problem
Via AB Newswire
Topics Animal Testing
News headline image
High-Impact Stocks DRK, VIVS, AEMD, GMG in the News
Via AB Newswire
Topics Artificial Intelligence Energy
News headline image
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
New data presented in Vienna highlights long-term repeat-dose modeling, mechanistic GI barrier profiling, and deconvolution of payload- and linker-dependent toxicities for complex modalities 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
Catch the Danger, Spare the Cure: Why VivoSim’s (NASDAQ: VIVS) 90%/95% Toxicity Results Matter
Via AB Newswire
Topics Artificial Intelligence
News headline image
VivoSim Labs (NASDAQ: VIVS): Predicting Drug Toxicity Before Human Clinical Trials
Via AB Newswire
News headline image
VivoSim Labs (NASDAQ: VIVS) Opens New Pharma Opportunity
Via AB Newswire
News headline image
Microcaps GPRO, FLYE, HKPD, VIVS to Watch Now
Via AB Newswire
Topics Artificial Intelligence Supply Chain
News headline image
VivoSim Labs to Add Rat Liver Model to NAMkind Platform
New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from risks that may translate to humans 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
IGC Pharma (NYSE: IGC) Target Raised on Alzheimer’s 2027 Outlook
Via AB Newswire
Topics Artificial Intelligence
News headline image
VivoSim Labs (NASDAQ: VIVS): 10,000 Compounds to 1 Drug with AI-Powered 3D Human Toxicology
Via AB Newswire
Topics Artificial Intelligence
News headline image
Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now
Via AB Newswire
Topics Artificial Intelligence
News headline image
VivoSim Labs (NASDAQ: VIVS) Research Report Highlights AI-Powered Drug Toxicity Platform, FDA NAM Momentum
Via AB Newswire
Topics Animal Testing Artificial Intelligence
News headline image
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum
Via AB Newswire
Topics Animal Testing Artificial Intelligence
News headline image
VivoSim Labs (NASDAQ: VIVS) Emerges in Drug Toxicity Market as Revenue Growth Guidance Tops 500% – Plus More In Focus
Via AB Newswire
Topics Animal Testing Artificial Intelligence
News headline image
Oversold Stocks TOON, RMCF, PRSO, OFAL Offer Opportunity – See Why Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
VivoSim Provides Financial and Listing Compliance Update
From VivoSim Labs, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.